Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.

Massimiliano Petrini,Laura Ridolfi,Laura Fiammenghi,M. Napolitano,Anna Maria Granato,Valentina Ancarani,Elena Pancisi,Massimo Guidoboni,Stefania Nicoletti,Linda Valmorri,Angela Riccobon,Giuseppe Migliori,Franco Venanzi,Paolo Antonio Ascierto,Ruggero Ridolfi

Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.

2011

Massimiliano Petrini
Laura Ridolfi
Laura Fiammenghi
M. Napolitano
Anna Maria Granato
Valentina Ancarani
Elena Pancisi
Massimo Guidoboni
Stefania Nicoletti
Linda Valmorri
Angela Riccobon
Giuseppe Migliori
Franco Venanzi
Paolo Antonio Ascierto
Ruggero Ridolfi

e13029 Background: Cytolytic T lymphocytes (CTL) able to kill tumor cells are efficiently induced by Dendritic Cells (DC); however, immunosuppressive factors, as CD4+CD25+FoxP3+ T lymphocytes (T-re...

Keywords:

Melanoma
Temozolomide
Dendritic cell
Pathology
Vaccination
Immunology
Medicine
Cytolysis
FOXP3
CTL*
IL-2 receptor
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations